Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 29.56
-0.64 (-2.12%)
May 28, 2026, 10:00 AM HKT
Everest Medicines Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Everest Medicines stock has a consensus rating of "Buy" and an average price target of $49.72. The average 1-year stock price forecast is 68.20% higher than the current stock price, while the lowest is $25.48 (-13.80%) and the highest is $68.76 (+132.61%).
Price Target: $49.72 (+68.20%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 18, 2026.
Analyst Ratings
The average analyst rating for Everest Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $84.00 | Buy | Maintains | $84.00 | +184.17% | Apr 18, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $55.00 | Buy | Maintains | $55.00 | +86.06% | Apr 5, 2026 |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. The data is sourced from Wall Street analysts. Data sources.